Journal of Clinical Oncology
Articles in this Issue
Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.
1062 Background: wP is commonly used for treating solid tumors as a single agent or in combination with targeted agents. However, it has an unfavorable be...
Real world data of maintenance treatment in homologous recombination (HR)–proficient HGSOC.
e17610 Background: Poly (ADP)-ribose polymerase (PARP) inhibitors with or without bevacizumab have increased 5-year overall survival to over 50% in homolo...
Preliminary efficacy results from an ongoing phase I/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced/metastatic solid tumors.
3082 Background: Epigenetic gene regulation, including arginine methylation holds significant promise in immunomodulation and long survival outcomes. It r...
Lung cancer screening for high-risk patients: A quality improvement initiative to improve guideline adherence in real-world primary care practices.
e22527 Background: Lung cancer remains the leading cause of cancer-related deaths in the US, but early detection through screening offers a high cure rate...
Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma.
4128 Background: Microvascular invasion (MVI) is currently recognized as a pathological feature strongly associated with HCC recurrence. However, its pred...
Demographic and regional trends in multiple myeloma and cardiovascular disease–related mortality among adults age 35 and older in the United States from 1999 to 2020: A CDC WONDER analysis.
e19565 Background: Approximately 7.5% of patients with multiple myeloma encounter cardiovascular diseases. Despite the substantial prevalence and establis...
Trends in cardiovascular disease mortality among pancreatic cancer patients in the US (1999–2023): Uncovering hidden comorbidities and their impact.
e16405 Background: Pancreatic cancer, a highly lethal malignancy, unequally impacts middle-aged populations and often coexists with cardiovascular disease...
Investigation of pegargiminase targeting the Fanconi anemia pathway and its role in DNA double-strand breaks induced by melphalan in uveal melanoma.
e15114 Background: Uveal melanoma (UM) is a hard-to-treat argininosuccinate synthetase 1 (ASS1)-deficient cancer with approximately 50% of patients succum...
Effect of exosome-derived lncRNA on MAL <sup>+</sup> CTL apoptosis in remodeling of the immune microenvironment in HPV <sup>+</sup> penile squamous cell carcinoma.
e17022 Background: Patients with HPV + PSCC have a poor prognosis, and the immune escape mechanisms remain a major challenge in im...
IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
8022 Background: In metastatic NSCLC (mNSCLC), genomic alterations (MUT) are well studied and have led to the development of efficacious new drugs. Howeve...
Use of BAFFR CAR-T to treat B cell leukemia/lymphoma and auto-immune diseases.
6523 Background: BAFFR (B-cell Activating Factor Receptor) is a member of the tumor necrosis factor (TNF) receptor superfamily and is almost exclusively e...
Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.
TPS4622 Background: Pts with muscle-invasive UC of the bladder or upper genitourinary tract who undergo radical cystectomy or nephroureterectomy are at hi...
Qualifying ADCs and multispecific therapeutic targets with a novel Agentic AI Insight platform.
e15179 Background: While genomic alterations are critical biomarkers for predicting response to targeted therapies, several novel classes of therapeutics...
Fear of recurrence among uninsured and underrepresented prostate cancer survivors of the Men's Health Study.
e17157 Background: The California Department of Public Health has funded the IMPACT program since 2001 to support low-income, uninsured, or underinsured C...
Which neoadjuvant treatment is best for locally advanced esophageal cancer? a systematic review and network meta-analysis.
e16121 Background: In recent years, perioperative treatment strategies for locally advanced esophageal cancer (LAEC) have become more diverse, including n...
Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial.
1552 Background: Confidently anticipating an overall survival (OS) benefit in cancer care and therapeutic research is a defining challenge. AI tools may o...
A phase II study of sacituzumab govitecan for advanced esophageal squamous cell carcinoma patients (SG-ESCC).
TPS4208 Background: Esophageal squamous cell carcinoma (ESCC) remains a significant global health challenge, particularly in Asia. There are limited treat...
Liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer: A multicenter, phase I/II trial.
e15545 Background: lrinotecan-based chemotherpy is a standard treatment in metastatic colorectal cancer (mCRC). Liposomal irinotecan is a nanoliposomal fo...
Use of a large language model (LLM) for pan-cancer automated detection of anti-cancer therapy toxicities and translational toxicity research.
1558 Background: Understanding why patients develop adverse events to anti-cancer therapies and predicting the occurrence of these toxicities has lagged b...
Environmental PFAS exposure as an understudied social determinant of health for endometrial cancer disparities: A geospatial study in Florida.
10564 Background: Endometrial cancer (EC) is the most common gynecological malignancy in the U.S. Although overall survival rate...
Real-world outcomes of perioperative chemotherapy versus neoadjuvant chemoradiation in patients with esophageal or gastroesophageal junction adenocarcinoma assessed using the NCDB.
e16085 Background: In the CROSS trial, chemoradiation therapy (CRT) prior to esophagectomy resulted in a marginal survival...
Mortality trends from hepatocellular carcinoma associated with non-alcoholic fatty liver disease in the United States, 1999–2020: An analysis of the CDC WONDER database.
e16217 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, with non-alcoholic fatty liver disease (NAFLD) emerging as...
A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10.
TPS2700 Background: Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand that is aberrantly expressed on the surface of tumor cells, in particular on...
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.
4108 Background: Advanced-stage hepatocellular carcinoma (HCC) is usually associated with poor survival outcomes. Rapid tumor control usually benefits lon...
Distinct genomic landscape of Lynch syndrome–associated urothelial cancer.
4582 Background: Lynch syndrome (LS) is a hereditary cancer predisposition syndrome caused by DNA mismatch repair (MMR) deficiency and associated with a 1...